Introduction
============

In the past decade, we have witnessed a revolution in understanding bone biology. Major progress has also been achieved in fracture risk estimation and prevention of fractures. How does this progress translate into daily clinical practice? First, case finding of subjects at highest risk for fractures is now possible at the individual patient level, using clinical bone- and fall-related risk factors, with and without bone mineral density (BMD). Second, prevention of vertebral and nonvertebral fractures, including hip fractures, is now possible by optimizing calcium homeostasis and by appropriate medication in well-selected patients with a high risk of fracture. Recent studies indicate new possibilities for case finding, such as *in vivo*structural analysis of bone microarchitecture, and new molecular targets to rebalance bone remodeling. Here, we review recent progress in case-finding strategies and in the evidence that the risk of first and subsequent fractures can be prevented in daily clinical practice.

The Fracture Risk Assessment Tool for calculating the individual 10-year fracture risk
======================================================================================

The clinical expression of osteoporosis is a fragility fracture, but bone loss in and of itself is asymptomatic, which has led to the description of osteoporosis as a \'silent thief\'. The asymptomatic nature of bone loss suggests that osteoporosis cannot be detected before a fragility fracture occurs, unless BMD is measured. Indeed, BMD is related to bone strength and low BMD is a major risk factor for fractures. However, most patients presenting with a fracture do not have BMD-based osteoporosis, defined according to the World Health Organization (WHO) definition as a T score of -2.5 or below \[[@B1]\]. Many qualities of bone, other than low BMD, are involved in fracture risk such as structural and material components of bone and the cellular activities and molecular signals that regulate lifelong bone remodeling under control of mechanical load, hormones, growth factors, and cytokines. Some of these characteristics of bone are measurable in clinical practice (for example, BMD, bone size, vertebral deformities and fractures, and markers of bone turnover), but many are not (for example, material properties) or are just evolving (for example, microarchitecture by microcomputer tomography or magnetic resonance imaging). In addition, and independent of bone-related risks, extraskeletal risk factors such as fall risk contribute to fracture risk and are present in the majority of patients older than 50 years presenting with a clinical fracture \[[@B1]\].

Large-scale prospective population studies have enabled the specification of clinical risk factors for fractures that are independent of low BMD and have allowed quantification of their relative risks (RRs) for predicting fractures. Thus, many aspects of osteoporosis and fracture risk are clinically recognizable (such as age, gender, and body weight), even before a first fracture has occurred. However, RRs are difficult to apply in daily clinical practice since their clinical significance depends on the prevalence of fractures in the general population. From this observation and for the purpose of clinical application, the concept of the absolute risk (AR) of fractures has emerged and refers to the individual\'s risk for fractures over a certain time period (for example, over the next 10 years) \[[@B2]\].

During the last decade, the development of the Fracture Risk Assessment Tool (FRAX) algorithm as a clinical tool for calculation of fracture risk in the individual patient is a major achievement in the field of case finding \[[@B2],[@B3]\]. The FRAX is based on large-scale prospective population-based studies and includes age, gender, body weight and body mass index, a history of fracture, hip fracture in parents, current smoking, excessive alcohol intake, rheumatoid arthritis, glucocorticoid use, and other forms of secondary osteoporosis (Table [1](#T1){ref-type="table"}). The WHO developed FRAX especially for primary care physicians for calculating the individual 10-year risk of hip and major fractures (defined as clinical spine, forearm, hip, or humerus fracture) in daily practice in women and men, based on the above-mentioned clinical risk factors, with and without results of BMD measurement in the femoral neck.

###### 

Clinical risk factors and bone densitometry results that are included in the Fracture Risk Assessment Tool algorithm

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age
  Gender
  Body mass index
  History of fracture after the age of 45 to 50 years
  Parent with hip fracture
  Current smoking
  Alcohol intake of greater than 2 units per day
  Glucocorticoid use
  Rheumatoid arthritis
  Other causes of secondary osteoporosis:
   - Untreated hypogonadism in men and women, anorexia nervosa, chemotherapy for breast and prostate cancer, and hypopituitarism
   - Inflammatory bowel disease and prolonged immobility (for example, spinal cord injury, Parkinson disease, stroke, muscular dystrophy, and ankylosing spondylitis)
   - Organ transplantation
   - Type I diabetes and thyroid disorders (for example, untreated hyperthyroidism and overtreated hypothyroidism)
  Results of bone densitometry using dual-energy x-ray absorptiometry of the femoral neck.
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Strengths of the Fracture Risk Assessment Tool
----------------------------------------------

FRAX is based on a large sample of primary data of prospective population studies and takes into account variability in fracture probability between geographic regions. FRAX should not be considered a gold standard but rather a platform technology and provides an aid to enhance patient assessment. FRAX can be integrated in clinical practice in many countries worldwide, both in women and men. FRAX is therefore likely to become, in many countries, the most popular instrument for identifying women and men at highest risk for fractures.

FRAX has been included in guidelines as a tool for case finding for identifying postmenopausal women at high risk for fractures, for selecting subjects to measure BMD, and for treatment decisions. The National Osteoporosis Foundation (NOF) in the US and the National Osteoporosis Society (NOS) in the UK have recently updated their guidelines on postmenopausal osteoporosis in this context (Figure [1](#F1){ref-type="fig"}) \[[@B4],[@B5]\]. These groups have integrated FRAX and BMD for case finding of individuals at high risk for fracture and for treatment decisions. Both sets of guidelines make a clear distinction between postmenopausal women with and without a fracture history. This is a major step forward in the clinical applicability for postfracture treatment in patients presenting with a fracture. Based on the fracture risk profile, the NOS, together with the National Osteoporosis Guideline Group (NOGG) and the Royal College of Physicians, determined treatment thresholds at which fracture prevention became cost-effective (Figure [2](#F2){ref-type="fig"}) \[[@B2],[@B5]\].

![**Algorithms for case finding and drug treatment decisions in postmenopausal women with and without a history of fractures according to the National Osteoporosis Foundation (NOF) in the US and the National Osteoporosis Society (NOS) in the UK**. DXA, dual-energy x-ray absorptiometry; FRAX, Fracture Risk Assessment Tool. \*Previous fragility fracture, particularly of the hip, wrist and spine including morphometric vertebral fracture. \*\*Based on UK guidelines by NOGG.](ar2815-1){#F1}

![**Assessment and intervention thresholds based on the 10-year risk of major fracture, as proposed in the UK**\[[@B2]\]. BMD, bone mineral density. With kind permission from Springer Science+Business Media \[[@B5]\].](ar2815-2){#F2}

Postmenopausal women with a history of fractures
------------------------------------------------

The NOS advocates drug treatment in all postmenopausal women with a history of any fragility fracture (defined as distal radius, proximal humerus, spine \[including morphometric vertebral fracture\], pelvis \[pubic rami\], tibia, and ankle) \[[@B5]\]. The NOF advocates drug treatment in postmenopausal women with a vertebral or hip fracture (without need of BMD or FRAX for decisions about pharmacotherapy), but after a nonvertebral nonhip fracture, the NOF advocates performing a dual-energy x-ray absorptiometry (DXA) measurement and starting drug treatment in patients having osteoporosis and in patients with osteopenia when FRAX indicates a 10-year fracture probability of at least 3% for hip or at least 20% for major fractures. Thus, in postmenopausal women with a history of vertebral or hip fracture, neither set of guidelines uses FRAX for decisions about drug treatment (and neither does the NOS for after any fragility fracture), and both sets consider such fracture history by itself as a starting point for case finding and treatment decisions.

Postmenopausal women without a fracture history
-----------------------------------------------

The NOS advocates applying FRAX (without BMD) in all postmenopausal women. Women at high risk according to FRAX without BMD are then considered candidates for drug treatment. Women with an intermediate risk according to FRAX without BMD are recommended to have a DXA measurement, and when FRAX with BMD is above the intervention threshold according to the NOGG, drug treatment should be considered.

The NOF advocates using DXA in all women older than 65 years and in postmenopausal women younger than 65 years in whom there is concern about their fracture risk based on the presence of clinical risk factors. This approach suggests that all postmenopausal women under 65 years of age should be clinically classified as having at least one of the risk factors of FRAX. Treatment is then recommended in patients with osteoporosis, in patients with osteopenia when the FRAX indicates a 10-year risk of greater than 3% for hip fractures or greater than 20% for major osteoporotic fractures, and in other patients considered at high risk (on glucocorticoids, total immobilization). These upgraded guidelines indicate that FRAX is an emerging tool in clinical decision making about case finding, selecting patients for DXA, and treatment decisions in postmenopausal women without a fracture history. Patients with a fracture are considered at high enough risk to make treatment decisions without additional need for using FRAX. It is expected that FRAX will also be helpful in designing fracture prevention studies and in reimbursement issues. In a study from Switzerland, profiles of patients at increased probability of fracture beyond currently accepted reimbursement thresholds for bone BMD measurement by DXA and osteoporosis treatment were identified and constitute an additional group of patients in whom treatment should be considered \[[@B6]\].

Limitations of the Fracture Risk Assessment Tool
------------------------------------------------

In spite of its solid scientific basis and clinical attractiveness, FRAX has several limitations, as acknowledged by the authors (Table [2](#T2){ref-type="table"}) \[[@B2]\]. Meanwhile, FRAX has been integrated in guidelines/guidance in the US, UK, Europe, Canada, Germany, and Japan \[[@B2]\], but with different approaches for diagnostic and treatment thresholds, as shown above for the NOS and the NOF \[[@B4],[@B5]\]. Fracture reduction has been demonstrated in randomized controlled clinical trials in patients selected on the basis of the presence of a morphometric vertebral fracture, hip fracture, or a low BMD, but not on the basis of FRAX. Therefore, of great interest is the finding that fracture reduction was greater at higher fracture probabilities based on FRAX, with or without BMD. Antifracture efficacy was evident when baseline fracture probabilities for major fractures were greater than 20% in the clodronate trial (in preventing major fractures) \[[@B7]\] and greater than 16% in the bazedoxifene trial (in preventing clinical fractures), irrespective of whether BMD was used in the fracture calculation \[[@B2]\]. Further studies will be needed on the ability of treatment to reduce fracture risk in subjects at high risk for fractures based on FRAX in the absence of a morphometric vertebral fracture, hip fracture, or a low BMD, which is the case in most patients presenting with a nonvertebral fracture. Decisions on treatment thresholds will furthermore depend on factors related to health care providers and patients and the willingness of society to reimburse treatment as health economic aspects are becoming increasingly important to determine the cost-effectiveness of treatment. Meanwhile, the NOGG of the UK has indicated FRAX-based thresholds for measuring BMD and for treatment decisions, with and without BMD (Figure [2](#F2){ref-type="fig"}). The management algorithms proposed by the NOGG are underpinned by a health economic analysis applied to the epidemiology of fracture in the UK.

###### 

Limitations of the Fracture Risk Assessment Tool for case finding

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \- Factors not included in FRAX:
   • The \'dose effect\' of some risk factors
    • Glucocorticoid use (dose and duration)
    • Characteristics of previous fractures (location, number, and severity)
   • Fall risks
   • Vitamin D deficiency
   • Fluctuation over time of subsequent fracture
   • Markers of bone formation and bone resorption
   • How to identify patients with a vertebral fracture
   • Which laboratory tests are indicated (and in whom) to exclude secondary osteoporosis
  \- FRAX is applicable only in untreated patients.
  \- Inclusion of BMD results is limited to results of BMD in the femoral neck. However, total hip BMD can be used interchangeably with femoral neck BMD in women, but not in men.
  \- FRAX does not indicate which intervention is indicated at which level of 10-year fracture risk of hip or major fractures (for either nonpharmacological or drug treatment).
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMD, bone mineral density; FRAX, Fracture Risk Assessment Tool.

Fall-related risks were explicitly excluded from the FRAX calculations but were recognized as risks for fractures independently of bone-related risks, especially for non-vertebral fractures such as hip fractures. More than 80% of women and men presenting with a clinical fracture to the emergency unit have, beside bone-related risks, one or more fall-related risks and have, independently from BMD, a fourfold increased risk of a fall history during the previous year \[[@B1]\]. In an integrated bone- and fall-related risk evaluation tool for the estimation of the 5- and 10-year ARs for fractures in patients using glucocorticoids, a history of falls had a greater impact on fracture risk than any other evaluated risk, and its contribution to fracture risk was similar to, and independent of, using a high dose of glucocorticoids (prednisone greater than 15 mg/day) \[[@B8]\]. Thus, with FRAX, fracture risk calculation could be underestimated in patients with fall risks.

Subsequent fractures and postfracture mortality cluster in time: the need for immediate clinical attention in patients presenting with a fracture
=================================================================================================================================================

A history of nonvertebral fracture is associated with a doubling of the risk of a subsequent fracture, and the subsequent fracture risk is even quadrupled after a vertebral fracture. However, this re-fracture risk is not constant over time and is driven by the high, threefold to fivefold increase in the years immediately after a first fracture, followed by a gradual waning later on (Figure [3](#F3){ref-type="fig"}) \[[@B9]\]. This has been shown for repeat morphometric vertebral fractures, subsequent clinical spine, forearm, and hip fractures after hospitalization because of a vertebral fracture, repeat low trauma fractures in subjects older than 60 years, repeat clinical vertebral and nonvertebral fractures from menopause onwards, and repeat hip fractures \[[@B9]-[@B12]\]. As a result, it has been shown in long-term follow-up studies that 40% to 50% of all subsequent fractures occur within 3 to 5 years after a first fracture. The clinical implication is that patients older than 50 years presenting with a fracture need immediate attention to reduce the risk of a subsequent fracture. This is a situation in which it is important to take immediate action in fracture patients, such as a fracture liaison service and other initiatives in the field of postfracture care \[[@B13],[@B14]\]. It also indicates that, in such patients, treatment that has been shown to reduce fracture risk within the short term should be started \[[@B15]\].

![**Risk of first and subsequent fracture over time**. **(a)**Percentage of all first fractures from menopause onwards (grey line) and fractures subsequent to initial fractures (black line). **(b)**Relative risk of all subsequent fractures calculated as a mean from the time of first fracture (grey line) and per separate year of follow-up after a first fracture (black line).](ar2815-3){#F3}

An increased risk of mortality has been found after hip, vertebral, and several nonhip, nonvertebral fractures \[[@B16]\]. As for subsequent fracture risk, this increase in mortality is higher immediately after fracture than later on. In women and men older than 60 years, nearly 90% of excess deaths related to fracture over the 18 years of observation occurred in the first 5 years. Of the 5-year excess mortality, hip, vertebral, and nonhip, nonvertebral fractures were each associated with approximately one third of deaths. The major causes of death were related to cardiovascular and respiratory comorbidity \[[@B16]\].

Assessment of vertebral fractures: an opportunity to identify high-risk patients
================================================================================

Vertebral fractures are a special group of fractures. Morphometric vertebral fractures are the most frequent fractures in women and men older than 50 years \[[@B17]\] and their presence is a strong predictor of future vertebral, non-vertebral, and hip fracture risk \[[@B18]\]. Clinical vertebral fractures represent one out of three to four morphometric vertebral fractures and represent less than 10% of all fractures in patients presenting with a fracture to the emergency department \[[@B1]\]. Most morphometric vertebral fractures are not diagnosed until clinically suspected (for example, significant height loss, hyperkyphosis, protruding abdomen, rib-iliac crest distance of less than 2 cm, and acute or chronic back pain) and imaging by x-ray is performed. But even when lateral x-rays of the spine are available, vertebral fractures are often missed \[[@B18],[@B19]\].

Vertebral fracture assessment (VFA) is a new method to evaluate the presence of morphometric vertebral fractures and deformities using x-ray absorptiometry (Figure [4](#F4){ref-type="fig"}) \[[@B19]\]. With appropriate DXA devices, VFA can be performed at the occasion of a bone densitometry. Advantages are its low irradiation, the availability of semiautomatic image analysis tools to assist in measuring vertebral shapes of the individual vertebrae, its plan-parallel projection, and its high negative predictive value. Disadvantages include difficulties in measuring upper thoracic vertebrae due to overlying soft tissue and ribs.

![**Example of using dual-energy x-ray absorptiometry technology for vertebral fracture assessment**.](ar2815-4){#F4}

The prevalence of previously unknown morphometric vertebral fractures has been studied in various at-risk populations. In a recent study of women and men presenting with a nonvertebral fracture, one out of four had a prevalent morphometric vertebral fracture on VFA that was not recognized previously \[[@B14]\]. In one other study, the prevalence of morphometric vertebral fractures was 21% in postmenopausal women with osteopenia \[[@B20]\]. The authors concluded that the use of VFA contributed to better define the fracture risk in patients presenting with a nonvertebral fracture and in women with osteopenia and contributed to treatment decisions by identifying patients at high risk of fractures in the absence of BMD osteoporosis. VFA also helps to select patients in whom x-rays of the spine are indicated to differentiate changes in shape from normal variations and diseases such as Scheuermann disease, pathologic fractures, bone remodeling in the context of osteoarthritis, and developmental short vertebral height \[[@B19]\]. According to the International Society of Clinical Densitometry (ISCD), additional x-ray imaging is needed in cases of two or more mild (grade 1) deformities without any moderate or severe (grade 2 or 3) deformities, when lesions in vertebrae cannot be ascribed to benign causes, or when vertebral deformities are found in a patient with a known history of a relevant malignancy \[[@B19]\]. In patients with BMD-diagnosed osteoporosis, a baseline VFA is not necessary for treatment decisions but can be helpful to identify during follow-up whether a vertebral fracture is new or old \[[@B15]\]. Indications for VFA according to the ISCD are shown in Table [3](#T3){ref-type="table"}\[[@B19]\].

###### 

Indications for vertebral fracture assessment using x-ray absorptiometry \[[@B19]\]

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\. Postmenopausal women with low bone mass (osteopenia) by BMD criteria plus one of the following:
   - Age of greater than or equal to 70 years.
   - Historical height loss of greater than 4 cm.
   - Prospective height loss of greater than 2 cm.
   - Self-reported prior vertebral fracture (not previously documented).
   - Two or more of the following:
    Age of 60 to 69 years.
    Self-reported prior nonvertebral fracture.
    Historical height loss of 2 to 4 cm.
    Chronic systemic diseases associated with increased risk of vertebral fractures (for example, moderate to severe COPD, seropositive rheumatoid arthritis, and Crohn disease).
  2\. Men with low bone mass (osteopenia) by BMD criteria plus one of the following:
   - Age of 80 years or older.
   - Historical height loss of greater than 6 cm.
   - Prospective height loss of greater than 3 cm.
   - Self-reported vertebral fracture (not previously documented).
   - Two or more of the following:
    Age of 70 to 79 years.
    Self-reported prior nonvertebral fracture.
    Historical height loss of 3 to 6 cm.
    On pharmacological androgen deprivation therapy or following orchiectomy.
    Chronic systemic diseases associated with increased risk of vertebral fractures (for example, moderate to severe COPD, seropositive rheumatoid arthritis, and Crohn disease).
  3\. Women or men on chronic glucocorticoid therapy (equivalent to 5 mg or more of prednisone daily for 3 months or longer).
  4\. Postmenopausal women or men with osteoporosis by bone density criteria (total hip, femoral neck, or lumbar spine T score of not more than -2.5) if documentation of one or more vertebral fractures will alter clinical management.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMD, bone mineral density; COPD, chronic obstructive pulmonary disease.

Differential diagnosis in patients with osteoporosis or a fragility fracture or both
====================================================================================

Randomized controlled trials on fracture prevention in postmenopausal women exclude patients with secondary osteoporosis, except in studies in glucocorticoid users. However, patients with BMD-diagnosed osteoporosis or presenting with a clinical fracture or both often have contributors to secondary osteoporosis. FRAX includes a long list of causes of secondary osteoporosis that contribute to fracture risk independently of other clinical risks and BMD (Table [1](#T1){ref-type="table"}) \[[@B2],[@B3]\]. Differential diagnosis in the context of case finding therefore includes a thorough medical history and clinical examination. Based on FRAX, laboratory investigations can contribute to case finding, but FRAX does not give instructions on how to exclude other contributors to secondary osteoporosis that are frequently found in patients with osteoporosis or fractures or both \[[@B21],[@B22]\]. In patients with BMD-based osteoporosis or presenting with a clinical fracture or both, diagnostic evaluation is necessary and should include serum 25-(OH)D3, calcium, creatinine, thyroid-stimulating hormone, parathyroid hormone (PTH), testosterone (in men) and, of 24-hour urine, calcium and creatinine \[[@B21]-[@B23]\]. According to the clinical picture and suspicion, other serum measurements such as plasma cortisol, hemoglobin, white blood cell count, serum/urine protein electrophoresis, and selected other evaluations looking for secondary causes are indicated.

Only limited studies about the prevalence of secondary osteoporosis in daily practice have been published during the last decade. In patients referred for DXA in the clinical context of an osteoporosis clinic, contributors to secondary osteoporosis were already documented in one out of three postmenopausal women with osteoporosis \[[@B21]\]. In the group of otherwise presumably healthy women, previously undiagnosed contributors were found in an additional 30% of women \[[@B21]\]. In women and men presenting with a clinical fracture at the emergency unit and having BMD osteoporosis, 42% had contributors to secondary osteoporosis, mainly vitamin D deficiency \[[@B22]\].

Vitamin D deficiency is endemic worldwide \[[@B24]\] but is not included in the FRAX algorithm. Vitamin D deficiency was found to be the main contributor to secondary osteoporosis in postmenopausal women with BMD osteoporosis \[[@B21]\], in women and men presenting with a clinical fracture and having BMD osteoporosis \[[@B22]\], and in patients presenting with a hip fracture \[[@B25]\]. Recent data indicate that vitamin D is an independent risk for fractures \[[@B26]\], and meta-analyses indicate that correction of vitamin D deficiency results in a decreased fall and fracture risk \[[@B27],[@B28]\], but the effects depend on the dose of vitamin D and the target population \[[@B29]\]. Frail older people confined to institutions may sustain fewer hip fractures if given vitamin D with calcium. Vitamin D alone is unlikely to prevent fracture \[[@B30]\].

It is still a matter of debate which dose of vitamin D~3~(or potentially D~2~) supplementation is necessary/optimal, taking into account baseline vitamin D status and the desired serum levels to be achieved by supplementation \[[@B31]-[@B33]\]. Clearly, an intake of 400 IU/day is not sufficient \[[@B31]-[@B34]\]. A daily intake of 800 to 1,600 IU in healthy adults will increase serum levels above 75 nmol/L in half of the population \[[@B33]\]. Others suggest that 1,000 to 1,200 IU/day is necessary in addition to typical food and cutaneous inputs to achieve a target serum level of 80 nmol/L (32 ng/mL) \[[@B31]\].

Lifelong milk intake is not related to fracture risk \[[@B35]\], but in several reviews, the necessity of addition of calcium to vitamin D for fracture prevention was stressed and a dose of 1,000 to 1,200 mg/day was advocated \[[@B34],[@B36]\]. However, in studies published in 2008, supplements of 1,000 mg calcium/day in healthy postmenopausal women \[[@B37]\] and healthy men \[[@B38]\] with a mean baseline calcium intake of 800 mg/day were associated with an increased risk of vascular events, including myocardial infarction. These studies raised considerable controversy and suggested the need for further research \[[@B39]\]. In this context, it is reassuring that, when intake of vitamin is sufficient, the need for D~3~calcium intake is considered to be lower \[[@B32],[@B40]-[@B42]\]. Indeed, if dietary calcium is a threshold nutrient, as suggested by Heaney \[[@B41]\], then the threshold for optimal calcium absorption may be at a lower calcium intake when vitamin D nutrition is higher. Until well-designed studies address the current uncertainties, the possible detrimental effect (for example, hypercalcemia and its complications) of higher-than-recommended calcium intake should be balanced against the likely benefits of calcium on bone, particularly in older women \[[@B43]\]. It should be noted that all clinical trials with drug therapy for osteoporosis (bisphosphonates and so on) have been conducted with the concomitant use of calcium and vitamin D supplementation.

It is generally considered that secondary causes of osteoporosis are more common in men than women, with the exception of hormone deficiency, which is characteristic after menopause, whereas andropause, depending on its definition, is found in only a subgroup of older men or men with osteoporosis \[[@B44]\]. Hypogonadism resulting from the treatment of breast and prostate cancer is recognized as an emerging clinical problem \[[@B45]\]. Cancer treatment-induced bone loss with adjuvant endocrine therapy with an aromatase inhibitor or androgen deprivation can be considered a risk factor for the development of osteopenia, osteoporosis, and bone fracture, which can be mitigated by appropriate bisphosphonate therapy \[[@B45]\]. Other, less common, risk factors for osteoporosis and fractures but commonly present in patients with low BMD or presenting with a fracture and that are not part of FRAX include the use of medications (for example, anticonvulsants, primary hyperparathyroidism, renal insufficiency, gastrectomy, Cushing syndrome, dementia, and chronic pulmonary and/or liver diseases).

Fall prevention measures
========================

Vitamin D supplements decrease the risk of falls, as discussed above. Extraskeletal measures that are advocated in guidelines include avoidance of immobility, stimulation of weight-bearing exercise, and physiotherapy. Recent systematic reviews indicate that these measures still need more research to specify their role in the prevention of fractures. Fall prevention interventions that are likely to be effective in older people are now available \[[@B46]\]. Less is known about their effectiveness in preventing fall-related injuries, and no data that fall prevention decreases the risk of fracture are available. Exercise interventions reduce the risk and rate of falls in older people living in the community \[[@B47]\]. The role of hip protectors remains controversial in light of low acceptance and low acceptability and adherence due to discomfort and practicality \[[@B48],[@B49]\].

Advances in osteoporosis pharmacotherapy: more than a decade of progress
========================================================================

Beyond the need for sufficient calcium, vitamin D, and exercise, the past decade has seen an emergence of new data supporting a growing armamentarium of therapeutics for osteoporosis. Pharmacological therapies useful in the prevention and treatment of osteoporosis affect bone remodeling by either inhibiting bone resorption or enhancing bone formation. The majority of the agents currently licensed in both the US and other countries inhibit bone resorption. Recombinant PTH (teriparatide), on the other hand, is a bone anabolic agent. Strontium ranelate has a dual effect on bone remodeling: it stimulates bone formation and inhibits bone resorption, as shown in animal models, but is not available in the US. Despite an increasing number of well-designed studies providing evidence for pharmacotherapies in reducing primary or secondary fracture risk, many high-risk patients are not treated \[[@B50]\], and for patients who initiate therapy, adherence to therapy is commonly below 50% at 1 to 2 years \[[@B51]\].

Estrogen
--------

Estrogen has a direct effect on bone mass through receptors on osteoclasts and other bone cells and it results in lowered bone turnover and resorption. Observational studies have suggested a 25% to 70% risk reduction for fractures associated with the use of estrogen replacement therapy (ERT) \[[@B52]-[@B55]\]. Results from the Women\'s Health Initiative (WHI), a study of over 16,000 postmenopausal women, convincingly confirmed a significant risk reduction of hip fractures attributed to combined conjugated equine estrogen and medroxyprogesterone (RR = 0.66, 95% confidence interval \[CI\] 0.45 to 0.98) \[[@B56]\] as well as estrogen alone in those women who had undergone hysterectomy \[[@B57]\]. In addition to its beneficial effects on bone, ERT raises high-density lipoproteins and lowers low-density lipids in post-menopausal women \[[@B58],[@B59]\]. Although a number of observational studies, including the Nurses Health Study \[[@B60]\], have reported a 35% to 80% reduction in cardiovascular events and prolonged survival among women with coronary heart disease compared with nonusers \[[@B61]-[@B65]\], results from the WHI and other studies of both primary and secondary cardiovascular prevention refute this conclusion \[[@B56],[@B62],[@B66],[@B67]\]. Data from the WHI found a nearly 30% increased risk of coronary heart disease and an over 40% increased risk of stroke.

Beyond heart disease, three significant concerns with estrogen are an increased risk of thromboembolic events \[[@B68]\], hyperplastic effects on the endometrium (potentially leading to endometrial cancer), and a heightened risk for breast cancer. The WHI \[[@B56]\] and other studies \[[@B69]\] have shown a 26% to 35% increased risk of breast cancer. Some \[[@B70]\], but not all \[[@B71]\], studies suggest that invasive breast tumors that develop among estrogen users have a more favorable histologic prognosis and that lobular cancer is more common than ductal cancer \[[@B72]\].

The decision to initiate ERT should be individualized and based on a balanced assessment of risk and benefits by the physician and patient \[[@B73],[@B74]\]. Lower-dose estrogen can increase bone mass, may have a lower adverse effect profile, and raises interest in further study of this possible approach \[[@B75],[@B76]\]. The proven increased risks for breast cancer and hypercoagulability and the higher risks of both primary and secondary cardiovascular disease (at least among older women) offset bone benefits and have substantially diminished enthusiasm for long-term higher-dose estrogen historically used by many patients. Although questions about the relative benefit and risks of different estrogen types, routes of administration (oral versus transdermal), administration protocols (opposed by progestins versus unopposed), and variable risk profiles based on a woman\'s age and comorbidities persist, current recommendations support restricting the use of estrogen in most women to the perimenopausal period \[[@B77],[@B78]\] and not with the primary aim to prevent fractures in the context of treatment of osteoporosis. Furthermore, the growing array of alternative bone-directed medications now available further restrict the estrogen niche.

Selective estrogen receptor modulators
--------------------------------------

Selective estrogen receptor modulators (SERMs) are non-steroidal synthetic compounds that have estrogen-like properties on the bone and cardiovascular systems yet are estrogen antagonists to the breast and, in some cases, the endometrium. The first SERM developed both for breast cancer prevention and for osteoporosis, raloxifene, is now licensed in many countries for osteoporosis \[[@B79]\]. After 3 years of follow-up in the Multiple Outcomes of Raloxifene Evaluation (MORE), a multicenter study of over 7,700 postmenopausal women with at least one vertebral fracture or osteoporosis on the basis of a T score of -2.5 or below, 60 mg/day of raloxifene reduced vertebral fracture risk by 30% \[[@B80]\]. This decline in fracture risk at the spine was of a magnitude similar to that seen with more potent antiresorptive agents such as the aminobisphosphonates and emphasized the importance of attenuation of bone turnover, in addition to effects on BMD, for fracture risk reduction \[[@B81],[@B82]\]. Similar to tamoxifen, the risk of invasive breast cancer was decreased by 72% during the MORE study \[[@B83],[@B84]\], particularly among women with higher estradiol levels \[[@B85],[@B86]\]. Hot flashes and other menopausal symptoms may recur on raloxifene. Also similar to estrogen, with raloxifene, there is an increase in lower-extremity edema as well as a roughly threefold increased risk of deep venous thrombosis \[[@B80]\]. Additional SERMs, such as bazedoxifene and lasofoxifene, are under development. Bazodoxifene decreases vertebral fracture risk to a degree similar to that of raloxifene (approximately 40% over a 3-year period \[[@B87]\]) and, in a *post hoc*analysis, reduced the risk of nonspine fractures in a subgroup of patients with high risk for fractures based on the FRAX algorithm \[[@B2]\]. Preliminary results from the PEARL (Postmenopausal Evaluation And Risk reduction with Lasofoxifene) trial showed significant reductions compared with placebo in vertebral and nonvertebral (but not hip) fracture risk as well as in estrogen receptor breast cancer with the 0.5 mg dose \[[@B88]\]. This is the only SERM, to date, that has primary data on nonvertebral fracture risk reduction. Of potential concern, a small rise in overall mortality was reported in the 0.25 mg dose but not in the 0.5 mg dose.

Calcitonin
----------

Randomized controlled trials of both injectable \[[@B89]-[@B91]\] and intranasal \[[@B92]-[@B95]\] calcitonin for treatment of established postmenopausal osteoporosis have consistently shown either stabilization of BMD or small, but significant, increases in vertebral BMD of approximately 1% to 3% on 200 IU daily for over 3 to 5 years. Beneficial BMD effects at the hip have not yet been reported. Modest increases in vertebral BMD with intranasal calcitonin are accompanied by significant declines in biochemical measures of bone resorption \[[@B96]\]. A 5-year multicenter study of 1,255 postmenopausal women showed a 36% reduction in vertebral fractures in the 200 IU, but not in the 100 or 400 IU, dosage group. Interpretation of study results was further limited by an approximately 50% dropout rate \[[@B97],[@B98]\]. Nasal calcitonin is generally well tolerated, with occasional rhinitis. Headache, flushing, nausea, and diarrhea have been reported more commonly with subcutaneous rather than with intranasal calcitonin. On the basis of data that are somewhat weaker than those of osteoporosis drugs (including the absence of data on hip or nonvertebral fracture risk reduction) along with emerging new therapeutic agents, calcitonin has been relegated to a second- or third-line agent for osteoporosis prevention and treatment.

Bisphosphonates
---------------

Bisphosphonates are potent inhibitors of bone resorption and fractures when administered orally or by intravenous infusion \[[@B99]\]. Variations in the structure of the amino side chains of these drugs affect their pharmacological activity. All oral bisphosphonates are poorly absorbed, with bioavailability of less than 1%. These agents bind tightly to hydroxyapatite crystals of bone, where they have a variable but generally long skeletal retention (approximately 10 years for alendronate). Over prolonged administration, a regional paracrine effect of continuously deposited and recycled bisphosphonates may partially account for a lack of rapid loss of BMD gains at some, but not all, skeletal sites when these agents are discontinued \[[@B100]-[@B102]\]. The nitrogen-containing bisphosphonates (that is, alendronate, risedronate, and zolendronate) have variable affinity for bone and function as antiresorptive agents by variable enzyme inhibition, impairing cholesterol metabolism of the osteoclast and leading to cytoskeletal alterations and premature osteoclast cell death via apoptosis \[[@B103],[@B104]\].

As a class, oral bisphosphonates may lead to gastrointestinal (GI) intolerance, particularly at low pH \[[@B105]\]. Most reported GI symptoms have been nonulcer dyspepsia, and in most clinical trials, there have not been significant differences between those exposed to bisphosphonates and those receiving placebo \[[@B106],[@B107]\]. There have been rare reports of severe esophagitis \[[@B108]\] and case reports of esophageal cancer in patients taking oral bisphosphonates \[[@B109]\]. Some small studies suggest that GI side effects may be fewer with risedronate than alendronate \[[@B110]\].

The most common bisphosphonates licensed and used internationally are alendronate, risedronate, ibandronate, and zoledronic acid. These drugs are used in osteoporosis, Paget disease, myositis ossificans progressiva, heterotopic ossification, multiple myeloma, other malignancies with bone metastasis, and hypercalcemia. Alendronate, risedronate, and zoledronic acid have all been shown to improve BMD among patients receiving glucocorticoids \[[@B111]-[@B114]\].

Alendronate was the first aminobisphosphonate approved by the US Food and Drug Administration for the treatment and prevention of osteoporosis. Postmenopausal women receiving 10 mg/day of alendronate showed a lumbar spine BMD increase of 7% to nearly 9% over a 2-year period \[[@B115],[@B116]\]. Smaller, but still significant, changes were seen at the femoral neck and trochanter. In early postmenopausal women, 5 mg/day of alendronate prevented the loss of BMD at the spine, hip, and total body \[[@B117]\]. In a separate study, the 5 mg/day dose prevented bone loss to nearly the same extent as an estrogen-progestin combination (estrogen effect was 1% to 2% greater than 5 mg) \[[@B118]\]. Increases in spinal BMD with alendronate continue for up to 7 years of daily therapy \[[@B119]\]. Daily alendronate has a similar benefit and adequate tolerability even among older female residents of long-term care facilities \[[@B120]\]. A once-weekly preparation of alendronate has greatly exceeded daily administration based on BMD efficacy, improved ease of use, and tolerability that is equivalent to or better than daily therapy \[[@B121],[@B122]\]. Among 2,027 older women with at least one prior vertebral fracture and low femoral neck BMD in the Fracture Intervention Trial (FIT), alendronate had significant 47% and 51% reductions in morphometric vertebral and hip fractures, respectively \[[@B123]\]. In FIT subjects without prevalent vertebral fractures, alendronate 10 mg decreased radiographic vertebral fractures by 44% \[[@B124]\]. A multinational study of alendronate similarly identified a 47% risk reduction for nonvertebral fractures \[[@B125]\]. A long-term extension to the FIT study found that, with the exception of clinical vertebral fractures, fracture risk reduction at other skeletal sites was statistically indistinguishable in those receiving 5 years on followed by 5 years off of alendronate versus a full 10 years of therapy \[[@B100]\]. Further preliminary evaluation of these data has revealed that women with a femoral neck BMD T score of -2.5 or below at the 5-year mark had a higher risk of subsequent fractures \[[@B126]\]. Thus, the decision about whether to stop therapy with alendronate after a finite period of time is a topic of current controversy and in need of additional scientific data. In addition to prior duration of therapy, past adherence to therapy informs the risk of subsequent fractures \[[@B127]\].

Combination approaches of bisphosphonates with either estrogen or SERMs have shown equivalent or better BMD than with either therapy alone \[[@B128],[@B129]\], although concerns of oversuppression of bone remodeling and potential risk of inadequate repair of bone microdamage persist \[[@B130]\]. Alendronate can attenuate the loss of BMD seen after stopping hormone replacement therapy \[[@B131]\].

Alendronate clinical trials have shown no significant increases in serious adverse effects or significant GI adverse effects between treatment groups and placebo \[[@B106],[@B132]\]. In a study of glucocorticoid-induced osteoporosis, there was a small increase in nonserious upper GI adverse effects in those taking 10 mg but not 5 mg or placebo \[[@B111]\]. Results of bone histomorphometry indicate that alendronate decreases bone turnover in a dose-dependent manner but does not impair mineralization \[[@B121],[@B133],[@B134]\].

Risedronate is a pyridinyl bisphosphonate that increases bone mass and prevents fractures \[[@B135]\]. In separate US \[[@B136]\] and multinational \[[@B137]\] VERT (Vertebral Efficacy with Risedronate Therapy) studies, 1,226 and 2,458 postmenopausal women with at least one prior vertebral fracture were treated with 5 mg of risedronate. Women receiving risedronate experienced significantly fewer new vertebral (41% US and 49% multinational) and nonvertebral (39% and 33% reduction, respectively) fractures over a 3-year period \[[@B136]\]. In the Hip Intervention Program study, risedronate 5 mg significantly reduced hip fractures among women with confirmed low bone mass but not among those selected primarily on the basis of fall risks without documented osteoporosis \[[@B138]\]. Similar to alendronate, combined treatment with risedronate and estrogen resulted in additive improvement in BMD and further reduction in bone turnover \[[@B139]\]. Although the increases in BMD seen with risedronate were more modest compared with those of alendronate in one head-to-head comparator study \[[@B140]\], a fairly similar fracture effectiveness is believed to be due in part to the decrease in bone resorption, as evidenced by significant suppression of biochemical markers \[[@B141],[@B142]\]. Risedronate is taken daily, weekly, or (more recently) monthly and is generally well tolerated, with no significant differences in upper GI adverse events between those receiving placebo and risedronate \[[@B136],[@B143]\].

Ibrandronate either orally (daily or monthly schedules) or intravenously successfully reduced markers of bone turnover, increased BMD \[[@B144],[@B145]\], and reduced fractures of the vertebra (relative risk reduction \[RRR\] = 52%) \[[@B146]\]. Secondary analyses of persons in ibandronate studies with initial BMD at or below -3.0 showed that ibandronate had a protective effect on hip fracture risk reduction as well.

Zolendronic acid (zolendronate) is administered as a yearly intravenous infusion and significantly reduced both vertebral (RRR = 70%) and hip (RRR = 41%) fractures in a large multinational study \[[@B147]\]. A subsequent study examined women and men who had experienced a prior hip fracture and showed a significant reduction in subsequent clinical fractures along with a reduction in mortality \[[@B148]\]. Side effects may include an acute-phase response with myalgias and flu-like symptoms in 10% to 15% of patients receiving their first dose. These symptoms most commonly resolve within several days and are attenuated with acetaminophen, prior oral bisphosphonates, and repeated doses of the intravenous therapy. Patients receiving intravenous zoledronic acid must have adequate renal function (creatinine clearance of greater than 30 mL/minute) prior to getting this agent.

On the basis of largely uncontrolled reports of osteonecrosis of the jaw and newer questions about atypical femoral fractures, there is increasing scrutiny of particularly longer-term therapy with bisphosphonates as a class \[[@B149]\]. Osteonecrosis of the jaw has been reported in an estimated 2% of cancer patients receiving higher doses of predominately intravenous bisphosphonates for patients with malignancies in particular \[[@B150]\]. Cases also have been described in patients receiving bisphosphonates for osteoporosis. Although mechanisms are not confirmed for these two adverse outcomes, if a relationship is supported by further studies, this will have further impact on the idea of a \'drug holiday\' \[[@B151]\].

In summary, there have been a large number of studies documenting the efficacy of several bisphosphonates in terms of BMD gains and, of more importance, with regard to reduction of both vertebral and nonvertebral fractures. As a class, bisphosphonates are the most efficacious anti-resorptive agents currently available for bone. Despite a significant duration of worldwide use of bisphosphonates, a number of questions such as the necessary duration of therapy, long-term safety, and use among women of child-bearing potential as well as among children remain \[[@B152]\].

Parathyroid hormone
-------------------

When bone is exposed to elevated PTH levels continuously (e.g., hyperparathyroidism) it acts in a catabolic fashion. In contrast, exogenously administered intermittent PTH is anabolic stimulating skeletal remodeling and raising BMD both in rodent models and in human studies \[[@B153],[@B154]\]. PTH (residues 1 to 34) (teriparatide) significantly decreased the risk of vertebral (65% risk reduction in those on 20 μg/day) and nonvertebral fractures and increased BMD at all sites investigated, except for the radial shaft \[[@B155]\]. As a potential explanation for initial decreases in cortical bone density at sites such as the wrist, PTH initially increases intracortical porosity. It also leads to periosteal new bone formation and increases cross-sectional area, potentially increasing cortical bone strength \[[@B156],[@B157]\]. Teriparatide increases BMD in the spine of men by nearly 6% \[[@B158]\]. There is an enhanced effect on bone mass when PTH is sequentially followed by alendronate \[[@B159]\] or estrogen \[[@B160]\]. When PTH is compared directly with alendronate, there is a greater BMD increase seen with PTH in postmenopausal \[[@B161]\] as well as glucocorticoid-associated \[[@B162]\] osteoporosis. Although BMD increases with PTH occur even in the presence of potent antiresorptive agents such as alendronate \[[@B163]\], antecedent oral bisphosphonates started concurrently with PTH may attenuate bone mass improvement seen with PTH \[[@B164],[@B165]\]. PTH administered subcutaneously once a day has been associated with asymptomatic hypercalcemia, occasional nausea, and headache. Clinical trials of teriparatide were terminated early by the finding of osteosarcoma in Fisher rats \[[@B155]\]. Selective parathyroid receptor agonists and antagonists are under investigation and may play a future role in osteoporosis \[[@B166]\]. Due in part to the development of osteosarcoma in Fisher rats in the initial fracture trials (leading to their premature discontinuation), teriparatide at 20 μg/day is recommended for only a 24-month administration. It is used most commonly in adults with severe osteoporosis, many of whom have had fractures while on other antiosteoporotic agents or have had intolerance to bisphosphonates.

Strontium ranelate
------------------

Daily intake of strontium ranelate has been shown to reduce the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis or a prevalent vertebral fracture or both. In a *post hoc*analysis in women over 74 years old with low BMD at the femoral neck, it reduces the risk of hip fractures \[[@B167],[@B168]\]. Fracture reduction was still found after 5 years of treatment \[[@B169]\]. In a *post hoc*analysis in women older than 80 years, strontium ranelate reduced the risk of vertebral and nonvertebral fractures \[[@B170]\]. Strontium ranelate prevented quality-of-life impairment in postmenopausal women with established vertebral osteoporosis \[[@B171]\].

Examples of new osteoporosis targets and new mechanisms of action
=================================================================

Denosumab
---------

The discovery of the receptor activator of the nuclear factor-kappa B ligand RANKL/RANK/osteoprotegerin (OPG) pathway has opened new ways to target osteoclastic bone resorption. Clinical trials indicate that denosumab, a RANKL-specific recombinant humanized monoclonal antibody, is effective in suppressing bone resorption, resulting in an increase in BMD in postmenopausal women with low BMD \[[@B172]-[@B175]\]. The effect of denosumab on BMD and markers of bone remodeling was more pronounced than with weekly alendronate \[[@B176]\]. The effects on fracture reduction in postmenopausal osteoporosis are awaited from the recently finished FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months) study of nearly 8,000 women \[[@B177]\]. As compared with placebo, denosumab reduced the risk of new radiographic vertebral fracture by 68%, with a cumulative incidence of 2.3% in the denosumab group versus 7.2% in the placebo group (risk ratio 0.32, 95% CI 0.26 to 0.41; *P*\< 0.001). Denosumab significantly reduced the risk of hip fracture by 40% and also reduced significantly the risk of nonvertebral fracture by 20%. There was no increase in the risk of cancer, infection, cardiovascular disease, delayed fracture healing, or hypocalcemia, and there were no cases of osteonecrosis of the jaw.

In clinical trials with denosumab, overall adverse events were similar to placebo or comparators, indicating a favorable safety profile in these diseases, which are, up until now, available up to 4 years. Since the RANKL/RANK/OPG pathway is involved in the development of the immune system, data on long-term safety, particularly with respect to bacterial infection and neoplasms, will be needed \[[@B172]-[@B176],[@B178]\].

Catepsin K inhibition
---------------------

Cathepsin K is the most abundant cysteine protease expressed in the osteoclast and is believed to be instrumental in the bone matrix degradation necessary for bone resorption. Cathepsin K inhibitors represent a novel target for developing agents to treat osteoporosis and other disorders characterized by increased bone resorption \[[@B179]\].

Antisclerostin antibodies
-------------------------

The discovery that the Wnt signaling is a major pathway in osteoblast activity has resulted in a revolution in our understanding of the molecular mechanisms that are involved in bone formation. Preclinical studies have shown that sclerostin has a pivotal role as a negative regulator of bone formation in the aging skeleton and, furthermore, suggest that antibody-mediated inhibition of sclerostin represents a promising new therapeutic approach for the anabolic treatment of bone-related disorders, such as postmenopausal osteoporosis \[[@B180]\].

Summary
=======

In the past decade, we have witnessed a veritable revolution in osteoporosis diagnosis and therapeutics. Much of the success achieved has been motivated by an enhanced understanding of basic bone biology, a topic reviewed in a recent publication in the *Arthritis Research & Therapy*anniversary series. While bone density maintains great respect as one of the most valid and reliable measures of fracture risk, a renewed appreciation for the importance of other risk factors has led to new interest in AR models such as FRAX. New imaging approaches, including lateral VFA, have been added to the diagnostic armamentarium of bone health evaluation in an effort to identify fractures earlier. There is an increased appreciation of the severe consequences of prevalent fractures, not only of the hip but also of the much more common spine fractures. In particular, data substantiating the heightened risk of short-term re-fracture have increased the interest in secondary osteoporosis prevention. As international focus on osteoporosis has grown, accentuated diagnosis of alternate metabolic bone disorders has followed, and astute clinicians must be aware that there are many causes for low bone mass beyond osteoporosis. The use of sufficient calcium and attention to adequate vitamin D provide a necessary but often insufficient starting place for osteoporosis prevention and treatment. Aminobisphosphonates, taken orally or intravenously, have become the international mainstay of osteoporosis therapy. Questions exist about the very-long-term safety and the potential need for a drug holiday with some, if not all, of these compounds, despite their common use. Alternate therapeutic approaches that target suppression of bone resorption include historical use of sex steroids, SERMs, and now, less commonly, nasal calcitonin analogs. The mechanism of fracture reduction with daily strontium ranelate needs further study. Teriparatide is the first anabolic agent licensed for osteoporosis treatment but it must be given as a daily subcutaneous injection and used for a defined period of time. Therapeutic approaches on the horizon include biologic agents targeting RANKL, antibodies to sclerositin (a natural inhibitor of Wnt-mediated bone formation), and approaches to inhibit proteolytic enzymes such as catepsin K. While the past decade and a half has been a very exciting time in clinical osteoporosis care, the next decade should offer even greater promise for further improving our diagnostic and treatment approaches.

Abbrivations
============

AR: absolute risk; BMD: bone mineral density; CI: confidence interval; DXA: dual-energy x-ray absorptiometry; ERT: estrogen replacement therapy; FIT: Fracture Intervention Trial; FRAX: Fracture Risk Assessment Tool; GI: gastrointestinal; ISCD: International Society of Clinical Densitometry; MORE: Multiple Outcomes of Raloxifene Evaluation; NOF: National Osteoporosis Foundation; NOGG: National Osteoporosis Guideline Group; NOS: National Osteoporosis Society; OPG: osteoprotegerin; PTH: parathyroid hormone; RANK: receptor activator of nuclear factor-kappa B; RANKL: receptor activator of nuclear factor-kappa B ligand; RR: relative risk; RRR: relative risk reduction; SERM: selective estrogen receptor modulator; VFA: vertebral fracture assessment; WHI: Women\'s Health Initiative; WHO: World Health Organization.
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